Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
16566
post-template-default,single,single-post,postid-16566,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Home > Blogs  > Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

03 Jun Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Posted at 12:09h in Blogs by

In the Phase III study in 708  patients with HR–positive, HER2-negative advanced breast cancer who progressed during or after aromatase inhibitor therapy, the combination of AKT inhibitor capivasertib and fulvestrant showed significantly longer progression-free survival than with fulvestrant alone, both in the overall population (HR: 0.60) and among patients with AKT pathway–altered tumors (HR: 0.50). Overall survival was improved with the combination (HR: 0.74). (Ref: Turner NC, et al. N Engl J Med. June 1, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

No Comments

Sorry, the comment form is closed at this time.